Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.34 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.32 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1517836 | 1.00 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Hydrochloric Acid SCHEMBL4654220 | 1.00 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| SCHEMBL18477 | 0.98 | LTA4H (0.43) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| SCHEMBL1841835 | 0.98 | LTA4H (0.43) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| SCHEMBL1654337 | 0.98 | LTA4H (0.43) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Water SCHEMBL3912787 | 0.96 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| SCHEMBL6893763 | 0.96 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Water SCHEMBL27596082 | 0.96 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Hydrochloric Acid SCHEMBL23042780 | 0.89 | SLC1A1 (0.46) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Hydrochloric Acid SCHEMBL1143881 | 0.89 | SLC1A1 (0.39) | LTA4HNOS1NOS3NOS2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031415-A | Curcumin peptide dendrimer-Prussian blue nano enzyme-MSCs self-assembled preparation and preparation method and application thereof | 南京工业大学 | 2026-05-15 | — | — | CN | claimed |
| US-20250367332-A1 | PSMA-TARGETED RADIOACTIVE METAL COMPLEX CONTAINING NITROAROMATIC HETEROCYCLIC GROUP AND PREPARATION METHOD | UNIV BEIJING NORMAL (CN) | 2025-12-04 | — | — | US | claimed |
| CN-119301141-A | Compound of double-targeting tumor cells, preparation method and application thereof | 中国医学科学院北京协和医院 | 2025-01-10 | — | — | CN | claimed |
| CN-118924682-A | Difunctional dendritic lipopeptide nano micelle and preparation method and application thereof | 中国药科大学 | 2024-11-12 | — | — | CN | claimed |
| CN-118546180-A | Small molecule prodrug of clofarabine, preparation method and application thereof | 中国科学院苏州生物医学工程技术研究所 | 2024-08-27 | — | — | CN | claimed |
| CN-118546192-A | Cordycepin prodrug for resisting cancer, preparation method and application thereof | 中国科学院苏州生物医学工程技术研究所 | 2024-08-27 | — | — | CN | claimed |
| WO-2023231452-A1 | PSMA-TARGETING RADIOACTIVE METAL COMPLEX CONTAINING NITRO AROMATIC HETEROCYCLIC GROUP AND PREPARATION THEREOF | 北京师范大学 | 2023-12-07 | — | — | WO | claimed |
| CN-116903495-A | Preparation method of radioactive diagnostic drug ligand | 江苏华益科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-116507630-A | PSMA targeted radioactive metal complex containing nitro aromatic heterocyclic group and preparation thereof | 北京师范大学 | 2023-07-28 | — | — | CN | claimed |
| CN-109384715-B | Preparation method of small molecule inhibitor of prostate specific membrane antigen | 复旦大学附属肿瘤医院 | 2021-09-03 | — | — | CN | claimed |
| CN-110982012-B | Amphoteric acrylamide polymer flocculant and preparation method thereof | 江西科技师范大学 | 2021-08-06 | — | — | CN | claimed |
| CN-109134602-B | Solid phase preparation method of efficient prostate specific membrane antigen ligand PSMA-617 | 兰州大学 | 2021-07-02 | — | — | CN | claimed |
| CN-107245082-B | Synthesis method of 6-pterin folic acid | 天津阿尔塔科技有限公司 | 2020-04-17 | — | — | CN | claimed |
| CN-110982012-A | Novel amphoteric acrylamide polymer flocculant and preparation method thereof | 江西科技师范大学 | 2020-04-10 | — | — | CN | claimed |
| EP-1391449-A1 | Hydrolysis of amino acid diesters | PCBU Services, Inc. (US) | 2004-02-25 | — | — | EP | claimed |
| US-20040030177-A1 | Hydrolysis of amino acid diesters | PCBU SERVICES, INC. | 2004-02-12 | — | — | US | claimed |
| CN-122059928-A | Bifunctional chelators, PSMA ligand compounds, radiolabeled compounds and uses thereof | 广州医科大学附属第一医院（广州呼吸中心） | 2026-05-19 | — | — | CN | disclosed |
| CN-122031415-A | Curcumin peptide dendrimer-Prussian blue nano enzyme-MSCs self-assembled preparation and preparation method and application thereof | 南京工业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-4845216-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-07-04 | — | — | US | disclosed |
| US-4684653-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1987-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367332-A1 | PSMA-TARGETED RADIOACTIVE METAL COMPLEX CONTAINING NITROAROMATIC HETEROCYCLIC GROUP AND PREPARATION METHOD | PSMA1, PSMA2, PSMA7 | HDAC3 1787/4885HDAC1 222/4885HDAC2 1534/4885 |
| US-20040030177-A1 | Hydrolysis of amino acid diesters | DNPEP, ANPEP, DAO | HDAC3 4528/4885HDAC1 4072/4885HDAC2 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.